TT Electronics Launches Compact TAAM700 Medical Grade Power Supply

Offering More Power Per Cubic Inch than Industry Norms.

TT Electronics, a global provider of engineered technologies for performance critical applications, today announced the launch of its new 700 watt medical-grade enclosed power supply, the TAAM700. With a small 6.7 inch x 3.66inch footprint, the TAAM700 provides 17.8W per cubic inch and a wide operating temperature range from ‐30°C to +70°C forthermally challenged environments. Coupled with its compact size, TAAM700’s industry leading power density is ideal for space-constrained healthcare and industrial equipment, such as laser devices and robotics.

“The TAAM700 is an important addition to our already extensive medical power supply portfolio, offering 700 watt performance contrasted to the 650 watts available from other manufacturers,” said Frank Rene, general manager, power/IoT solutions, TT Electronics. “Where space is at a premium and high efficiency and safety/EMC compliance is critical, medical and industrial OEMs have a smarter option for industry leading power density and optimized footprint.”

This highly efficient and cost effective power supply provides 625-700 watts of continuous output power with a remote ON/OFF function, optional built‐in current share (configurable to 1.26kW) and features BF rated outputs. The TAAM700 is approved to UL/EN/IEC 60601-1. All models meet FCC PART 15 and EN55032 class B emission limits, and comply with UL, IEC, CE, UKCA and more.

The TAAM700 offers standard output voltages from 12VDC to 48VDC. All options are fully certified to applicable safety and EMC standards, reducing compliance risk, simplifying design-in, and accelerating time to market for end system designs.

View information on the TAAM700 here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.